Yan Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yan Ding has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Yali Wu
Department of Rheumatology and Immunology, Clinical Research Center of Pediatric Rheumatic and Immunological Diseases, Institute of Maternal and Child Health, Tongji Medical College, Wuhan Children’s Hospital (Wuhan Maternal and Child Health Care Hospital, Huazhong University of Science & Technology, Wuhan, China
10 shared publicationsWei Yin
Department of Rheumatology and Immunology, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 shared publicationsYang Zhou
Department of Rheumatology and Immunology, Clinical Research Center of Pediatric Rheumatic and Immunological Diseases, Institute of Maternal and Child Health, Tongji Medical College, Wuhan Children’s Hospital (Wuhan Maternal and Child Health Care Hospital, Huazhong University of Science & Technology, Wuhan, China
6 shared publicationsShasha Wang
Department of Rheumatology and Immunology, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
5 shared publicationsShiyu Li
Department of Rheumatology and Immunology, Clinical Research Center of Pediatric Rheumatic and Immunological Diseases, Institute of Maternal and Child Health, Tongji Medical College, Wuhan Children’s Hospital (Wuhan Maternal and Child Health Care Hospital, Huazhong University of Science & Technology, Wuhan, China
4 shared publicationsWen Yin
Department of Rheumatology and Immunology, Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science & Technology, China
3 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3918
The Autophagy–Inflammation Axis in Kawasaki Disease: Pathogenic Mechanisms and Translational Opportunities
Kawasaki disease (KD) represents the foremost cause of acquired pediatric heart disease, with coronary artery injury being the principal factor contributing to adverse prognoses. A significant clinical challenge is that 20–30% of patients demonstrate resistance to intravenous immunoglobulin (IVIG), which markedly elevates the risk of coronary artery lesions and long-term cardiovascular sequelae. Consequently, there is an urgent need to investigate novel pathogenic mechanisms beyond the conventional cytokine storm theory and to identify effective therapeutic targets. This review systematically summarizes the key role of the autophagy–inflammation axis in KD vasculopathy. Current evidence indicates that defective mitophagy and lysosomal dysfunction induce mitochondrial DNA release, resulting in overactivation of the NLRP3 inflammasome and cGAS-STING pathways, which amplify inflammatory responses and aggravate endothelial damage. The regulation of this axis is dynamic during both the acute and recovery phases and is influenced by metabolic reprogramming and epigenetic modifications, which may partially explain the lack of response to IVIG. Pharmacological agents, such as rapamycin and metformin, as well as natural compounds, such as resveratrol and urolithin A, have demonstrated beneficial anti-inflammatory effects in preclinical studies. Targeting the autophagy–inflammation axis represents a significant research direction with the potential to evolve into a promising therapeutic strategy. Mechanistically, restoring the balance of the autophagy–inflammation axis holds promise for mitigating coronary complications and improving long-term cardiovascular outcomes in children with KD; however, this prospect requires validation through prospective clinical studies.
- 19 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3918
Open AccessThe Autophagy–Inflammation Axis in Kawasaki Disease: Pathogenic Mechanisms and Translational Opportunities
Kawasaki disease (KD) represents the foremost cause of acquired pediatric heart disease, with coronary artery injury being the principal factor contributing to adverse prognoses. A significant clinical challenge is that 20–30% of patients demonstrate resistance to intravenous immunoglobulin (IVIG), which markedly elevates the risk of coronary artery lesions and long-term cardiovascular sequelae. Consequently, there is an urgent need to investigate novel pathogenic mechanisms beyond the conventional cytokine storm theory and to identify effective therapeutic targets. This review systematically summarizes the key role of the autophagy–inflammation axis in KD vasculopathy. Current evidence indicates that defective mitophagy and lysosomal dysfunction induce mitochondrial DNA release, resulting in overactivation of the NLRP3 inflammasome and cGAS-STING pathways, which amplify inflammatory responses and aggravate endothelial damage. The regulation of this axis is dynamic during both the acute and recovery phases and is influenced by metabolic reprogramming and epigenetic modifications, which may partially explain the lack of response to IVIG. Pharmacological agents, such as rapamycin and metformin, as well as natural compounds, such as resveratrol and urolithin A, have demonstrated beneficial anti-inflammatory effects in preclinical studies. Targeting the autophagy–inflammation axis represents a significant research direction with the potential to evolve into a promising therapeutic strategy. Mechanistically, restoring the balance of the autophagy–inflammation axis holds promise for mitigating coronary complications and improving long-term cardiovascular outcomes in children with KD; however, this prospect requires validation through prospective clinical studies.
- Open Access
- 2 October 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1602509
Clinical and genetic analysis of Majeed syndrome caused by LPIN2 complex heterozygous mutation and literature review
Background: Majeed syndrome is a rare autosomal recessive autoinflammatory disorder caused by LPIN2 mutations. It is characterized by chronic recurrent multifocal osteomyelitis (CRMO), congenital dyserythropoietic anemia (CDA), and, in some cases, neutrophilic dermatoses. Its rarity and overlap with juvenile idiopathic arthritis (JIA) often lead to delayed or incorrect diagnoses.Case presentation: We report a 3-year-10-month-old girl with recurrent swelling and pain of the knees and ankles, associated with low-grade fever and elevated inflammatory markers for over two years. Initially diagnosed and treated as JIA with NSAIDs, methotrexate, and adalimumab, she experienced only partial improvement. MRI revealed multifocal bone marrow edema consistent with CRMO, and laboratory results demonstrated mild microcytic anemia. These findings raised suspicion of a monogenic autoinflammatory disease. Whole-exome sequencing identified two novel LPIN2 variants: c.2349del (p.Glu784ArgfsTer8), inherited maternally, and c.2327+3A>G, inherited paternally. RNA analysis confirmed exon 17 skipping, carried out quantitative RT-PCR analysis of LPIN2 mRNA,establishing pathogenicity of the splice-site variant. Together with the clinical features, these findings confirmed the diagnosis of Majeed syndrome. A review of 35 previously reported patients demonstrated that most presented before age three with CRMO and recurrent fever, but the severity of CDA varied widely. IL-1 blockade remains the most effective treatment, with sustained remission reported in multiple cases.Conclusion: This case expands the mutational spectrum of LPIN2 and emphasizes the importance of early genetic testing in children with recurrent osteomyelitis and anemia refractory to standard therapy. Prompt recognition enables accurate diagnosis and timely initiation of IL-1–targeted therapy, which can markedly improve outcomes.
- 2 October 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1602509
Open AccessClinical and genetic analysis of Majeed syndrome caused by LPIN2 complex heterozygous mutation and literature review
Background: Majeed syndrome is a rare autosomal recessive autoinflammatory disorder caused by LPIN2 mutations. It is characterized by chronic recurrent multifocal osteomyelitis (CRMO), congenital dyserythropoietic anemia (CDA), and, in some cases, neutrophilic dermatoses. Its rarity and overlap with juvenile idiopathic arthritis (JIA) often lead to delayed or incorrect diagnoses.Case presentation: We report a 3-year-10-month-old girl with recurrent swelling and pain of the knees and ankles, associated with low-grade fever and elevated inflammatory markers for over two years. Initially diagnosed and treated as JIA with NSAIDs, methotrexate, and adalimumab, she experienced only partial improvement. MRI revealed multifocal bone marrow edema consistent with CRMO, and laboratory results demonstrated mild microcytic anemia. These findings raised suspicion of a monogenic autoinflammatory disease. Whole-exome sequencing identified two novel LPIN2 variants: c.2349del (p.Glu784ArgfsTer8), inherited maternally, and c.2327+3A>G, inherited paternally. RNA analysis confirmed exon 17 skipping, carried out quantitative RT-PCR analysis of LPIN2 mRNA,establishing pathogenicity of the splice-site variant. Together with the clinical features, these findings confirmed the diagnosis of Majeed syndrome. A review of 35 previously reported patients demonstrated that most presented before age three with CRMO and recurrent fever, but the severity of CDA varied widely. IL-1 blockade remains the most effective treatment, with sustained remission reported in multiple cases.Conclusion: This case expands the mutational spectrum of LPIN2 and emphasizes the importance of early genetic testing in children with recurrent osteomyelitis and anemia refractory to standard therapy. Prompt recognition enables accurate diagnosis and timely initiation of IL-1–targeted therapy, which can markedly improve outcomes.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 14161-14170
Risk Factor Analysis for Recurrence of Subacute Necrotizing Lymphadenitis in Children
Objective: To analyze the clinical features of subacute necrotizing lymphadenitis (SNL) in children and to explore the risk factors for recurrence. Methods: A retrospective case–control method was used to analyze 91 children with SNL admitted to Wuhan Children’s Hospital from June 2016 to December 2024. A total of 91 children diagnosed with SNL were included, including 8 cases with recurrence and 83 without recurrence. Sixty-seven of the 91 children with SNL included underwent lymph node pathology, and 24 did not undergo lymph node biopsy. The 91 clinically diagnosed SNL patients were divided into a recurrence group and a non-recurrence group. The 67 SNL cases that underwent lymph node pathological examination were also divided into recurrence and non-recurrence groups. Baseline information, clinical manifestations, and laboratory data were compared between the two groups, and univariate analysis was performed on the difference indicators. Binary logistic regression analysis was then used to explore the risk factors for recurrent SNL. Results: Analyze of 91 SNL patients revealed significant differences in age at onset (p=0.032), fever duration (p=0.01), IL-4 (p=0.037), and complement C3 (p=0.01) levels between recurrent and non-recurrent groups. Multivariate analysis identified older age (OR=1.32, CI: 1.04– 1.69, p=0.025) and elevated complement C3 (OR=41.96, CI: 1.68– 1049.04, p=0.023) as independent recurrence risk factors. In a distinct cohort of 67 children with pathologically confirmed SNL, significant differences emerged between recurrent and non-recurrent cases for age (p=0.023), fever duration (p=0.027), IL-4 (p=0.012), complement C3 (p=0.023), and serum creatinine (p=0.043). Here, multivariate analysis demonstrated that elevated complement C3 (OR=45.23, CI: 1.46– 1402.72, p=0.030) at diagnosis was an independent risk factor for recurrence. Conclusion: Older age of onset and elevated complement C3 may be risk factors for recurrence of SNL, with particular attention to elevated complement C3, and clinical follow-up is needed for this group of children.
- 1 October 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 14161-14170
Open AccessRisk Factor Analysis for Recurrence of Subacute Necrotizing Lymphadenitis in Children
Objective: To analyze the clinical features of subacute necrotizing lymphadenitis (SNL) in children and to explore the risk factors for recurrence. Methods: A retrospective case–control method was used to analyze 91 children with SNL admitted to Wuhan Children’s Hospital from June 2016 to December 2024. A total of 91 children diagnosed with SNL were included, including 8 cases with recurrence and 83 without recurrence. Sixty-seven of the 91 children with SNL included underwent lymph node pathology, and 24 did not undergo lymph node biopsy. The 91 clinically diagnosed SNL patients were divided into a recurrence group and a non-recurrence group. The 67 SNL cases that underwent lymph node pathological examination were also divided into recurrence and non-recurrence groups. Baseline information, clinical manifestations, and laboratory data were compared between the two groups, and univariate analysis was performed on the difference indicators. Binary logistic regression analysis was then used to explore the risk factors for recurrent SNL. Results: Analyze of 91 SNL patients revealed significant differences in age at onset (p=0.032), fever duration (p=0.01), IL-4 (p=0.037), and complement C3 (p=0.01) levels between recurrent and non-recurrent groups. Multivariate analysis identified older age (OR=1.32, CI: 1.04– 1.69, p=0.025) and elevated complement C3 (OR=41.96, CI: 1.68– 1049.04, p=0.023) as independent recurrence risk factors. In a distinct cohort of 67 children with pathologically confirmed SNL, significant differences emerged between recurrent and non-recurrent cases for age (p=0.023), fever duration (p=0.027), IL-4 (p=0.012), complement C3 (p=0.023), and serum creatinine (p=0.043). Here, multivariate analysis demonstrated that elevated complement C3 (OR=45.23, CI: 1.46– 1402.72, p=0.030) at diagnosis was an independent risk factor for recurrence. Conclusion: Older age of onset and elevated complement C3 may be risk factors for recurrence of SNL, with particular attention to elevated complement C3, and clinical follow-up is needed for this group of children.
- Open Access
- 18 August 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-11
Efficacy and safety of tacrolimus in the treatment of Henoch-Schönlein purpura nephritis: systematic review and meta-analysis
Henoch-Schönlein purpura nephritis (HSPN) is the most severe manifestation of Henoch-Schönlein purpura, significantly impacting patient outcomes. While immunosuppressive therapies like cyclophosphamide (CTX) and mycophenolate mofetil (MMF) are commonly used, evidence regarding the efficacy and safety of tacrolimus (TAC) in HSPN remains limited. This study presents the first systematic review and meta-analysis specifically evaluating the efficacy and safety of tacrolimus (TAC) in treating Henoch-Schönlein purpura nephritis (HSPN), aiming to fill a critical gap in evidence for clinical decision-making. This systematic review and meta-analysis, the first focused specifically on TAC in HSPN, included seven studies comprising 727 patients. A comprehensive search was conducted across multiple databases, including the Cochrane Library, PubMed, Embase, Medline, Web of Science, CNKI, Wanfang, SinoMed, VIP, and Embase. Studies comparing TAC with control treatments, such as CTX or MMF, in HSPN patients were included. Odds ratios (ORs) were calculated for dichotomous outcomes, while standardized mean differences (SMDs) with 95% confidence intervals (CIs) were used for continuous variables. Depending on heterogeneity, either random-effects or fixed-effects models were applied. Data synthesis was performed using RevMan software. A total of seven studies were included. TAC therapy significantly improved clinical efficacy in HSPN patients (OR = 4.43; 95% CI: 2.86–6.87; P < 0.001). Additionally, TAC significantly reduced urine protein levels (SMD = -1.17; 95% CI: -1.83 to -0.51; P < 0.001), serum creatinine (Scr) (SMD = -2.33; 95% CI: -3.00 to -1.65; P < 0.001), and blood urea nitrogen (BUN) (SMD = -1.49; 95% CI: -1.94 to -1.04; P < 0.001). Importantly, there were no significant differences in the incidence of adverse events between the TAC and control groups. This is the first systematic review and meta-analysis specifically evaluating TAC in HSPN, providing novel evidence that TAC is an effective and safe therapeutic option for these patients. Its potential advantages over conventional immunosuppressive therapies highlight the need for further high-quality, long-term randomized controlled trials to confirm these findings and establish TAC’s role in HSPN management.
- 18 August 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-11
Open AccessEfficacy and safety of tacrolimus in the treatment of Henoch-Schönlein purpura nephritis: systematic review and meta-analysis
Henoch-Schönlein purpura nephritis (HSPN) is the most severe manifestation of Henoch-Schönlein purpura, significantly impacting patient outcomes. While immunosuppressive therapies like cyclophosphamide (CTX) and mycophenolate mofetil (MMF) are commonly used, evidence regarding the efficacy and safety of tacrolimus (TAC) in HSPN remains limited. This study presents the first systematic review and meta-analysis specifically evaluating the efficacy and safety of tacrolimus (TAC) in treating Henoch-Schönlein purpura nephritis (HSPN), aiming to fill a critical gap in evidence for clinical decision-making. This systematic review and meta-analysis, the first focused specifically on TAC in HSPN, included seven studies comprising 727 patients. A comprehensive search was conducted across multiple databases, including the Cochrane Library, PubMed, Embase, Medline, Web of Science, CNKI, Wanfang, SinoMed, VIP, and Embase. Studies comparing TAC with control treatments, such as CTX or MMF, in HSPN patients were included. Odds ratios (ORs) were calculated for dichotomous outcomes, while standardized mean differences (SMDs) with 95% confidence intervals (CIs) were used for continuous variables. Depending on heterogeneity, either random-effects or fixed-effects models were applied. Data synthesis was performed using RevMan software. A total of seven studies were included. TAC therapy significantly improved clinical efficacy in HSPN patients (OR = 4.43; 95% CI: 2.86–6.87; P < 0.001). Additionally, TAC significantly reduced urine protein levels (SMD = -1.17; 95% CI: -1.83 to -0.51; P < 0.001), serum creatinine (Scr) (SMD = -2.33; 95% CI: -3.00 to -1.65; P < 0.001), and blood urea nitrogen (BUN) (SMD = -1.49; 95% CI: -1.94 to -1.04; P < 0.001). Importantly, there were no significant differences in the incidence of adverse events between the TAC and control groups. This is the first systematic review and meta-analysis specifically evaluating TAC in HSPN, providing novel evidence that TAC is an effective and safe therapeutic option for these patients. Its potential advantages over conventional immunosuppressive therapies highlight the need for further high-quality, long-term randomized controlled trials to confirm these findings and establish TAC’s role in HSPN management.
- Open Access
- 2 December 2024
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 12, 1459143
Kawasaki disease involving both the nervous system and cardiovascular system: a case report and literature review
Background: Kawasaki disease (KD), an acute self-limiting vasculitis, is the main cause of acquired heart disease. Timely diagnosis and treatment can mitigate the occurrence of complications and improve patient prognosis. Facial nerve paralysis (FNP) and ptosis are rare complications of KD and are rarely reported, but FNP is considered a high risk factor for coronary aneurysms. If giant coronary artery aneurysms are formed, clinicians should be vigilant when diagnosing the formation of systemic artery aneurysms (SAAs).Patient presentation: A 10-month-old girl with fever, diffuse rash, and conjunctival congestion was hospitalized locally, diagnosed with KD, and treated with intravenous infusion of gamma globulin (IVIG). She had fever again after 1 week of temperature stability, accompanied by conjunctival congestion, and was treated with a second dose of IVIG, but she still experienced recurrent fever. The day prior to admission, she developed facial asymmetry, left FNP, diffuse erythema and membranous peeling of the fingers of both hands. The patient's body temperature normalized after treatment with 20 mg/kg methylprednisolone, but cardiac ultrasound revealed progressive enlargement of the coronary artery aneurysms. On day 37of the illness, transient eyelid ptosis developed; fortunately, the left FNP and eyelid ptosis finally resolved, leaving no sequelae. Two years and eight months after onset, the patient developed bilateral humeral aneurysm.Conclusion: This is the first KD patient involving two neurological complications combined with giant coronary artery aneurysms and SAAs. KD needs to be considered in infants with unexplained recurrent fever who present with FNP or ptosis. FNP secondary to KD is a high risk factor for coronary artery aneurysms, so it is necessary to perform cardiac ultrasound for accurate diagnosis. KDs combined with giant coronary aneurysms require careful physical examination and noninvasive angiography during follow-up to detect SAA formation.
- 2 December 2024
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 12, 1459143
Open AccessKawasaki disease involving both the nervous system and cardiovascular system: a case report and literature review
Background: Kawasaki disease (KD), an acute self-limiting vasculitis, is the main cause of acquired heart disease. Timely diagnosis and treatment can mitigate the occurrence of complications and improve patient prognosis. Facial nerve paralysis (FNP) and ptosis are rare complications of KD and are rarely reported, but FNP is considered a high risk factor for coronary aneurysms. If giant coronary artery aneurysms are formed, clinicians should be vigilant when diagnosing the formation of systemic artery aneurysms (SAAs).Patient presentation: A 10-month-old girl with fever, diffuse rash, and conjunctival congestion was hospitalized locally, diagnosed with KD, and treated with intravenous infusion of gamma globulin (IVIG). She had fever again after 1 week of temperature stability, accompanied by conjunctival congestion, and was treated with a second dose of IVIG, but she still experienced recurrent fever. The day prior to admission, she developed facial asymmetry, left FNP, diffuse erythema and membranous peeling of the fingers of both hands. The patient's body temperature normalized after treatment with 20 mg/kg methylprednisolone, but cardiac ultrasound revealed progressive enlargement of the coronary artery aneurysms. On day 37of the illness, transient eyelid ptosis developed; fortunately, the left FNP and eyelid ptosis finally resolved, leaving no sequelae. Two years and eight months after onset, the patient developed bilateral humeral aneurysm.Conclusion: This is the first KD patient involving two neurological complications combined with giant coronary artery aneurysms and SAAs. KD needs to be considered in infants with unexplained recurrent fever who present with FNP or ptosis. FNP secondary to KD is a high risk factor for coronary artery aneurysms, so it is necessary to perform cardiac ultrasound for accurate diagnosis. KDs combined with giant coronary aneurysms require careful physical examination and noninvasive angiography during follow-up to detect SAA formation.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 10999-11008
Role of Pyroptosis in IVIG-Resistant Kawasaki Disease and the Establishment of a New Predictive Model
Background: Intravenous immunoglobulin (IVIG) resistance may be an increased risk of coronary artery lesions which is the serious complication of Kawasaki disease (KD). Early and accurate identification of IVIG-resistant patients has an important clinical value. Objective: To establish a new predicting model by detecting the pyroptosis markers with other clinical indicators. Methods: A total of 144 children with KD who were hospitalized in Wuhan Children’s Hospital from January 2022 to December 2022 were enrolled in this prospective study, among whom 120 had IVIG-sensitive KD and 24 had IVIG-resistant KD. NLRP3, ASC, CASP1, and GSDMD were quantified in peripheral blood cells of all children by using Real-time Quantitative Polymerase Chain Reaction (QRT-PCR) assay. The enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of cytokines like IL-1β and IL-18. Logistic regression analysis was performed to identify independent risk factors for resistance to IVIG in children with KD. These meaningful variables were assigned values based on odds ratios and became components of the new risk assessment model. The prediction efficiency of this model was tested and evaluated based on the receiver operating characteristic (ROC) curves. Results: 1. IVIG-resistant KD group had significantly lower mRNA expression of CASP1 than IVIG-sensitive KD group (P< 0.05). 2. IVIG-resistant KD group had significantly higher level of serum procalcitonin (PCT) and tumor necrosis factor-α (TNF-α) and lower level of serum natrium (Na) than the IVIG-sensitive KD group (P< 0.05). 3. The assessment model had a sensitivity of 91.7% and a specificity of 69.2% in the prediction of IVIG-resistant KD (P< 0.001). Conclusion: Combined examination by CASP1 and above laboratory indexes has clinical practical value for the diagnosis of IVIG-resistant KD.
- 1 December 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 10999-11008
Open AccessRole of Pyroptosis in IVIG-Resistant Kawasaki Disease and the Establishment of a New Predictive Model
Background: Intravenous immunoglobulin (IVIG) resistance may be an increased risk of coronary artery lesions which is the serious complication of Kawasaki disease (KD). Early and accurate identification of IVIG-resistant patients has an important clinical value. Objective: To establish a new predicting model by detecting the pyroptosis markers with other clinical indicators. Methods: A total of 144 children with KD who were hospitalized in Wuhan Children’s Hospital from January 2022 to December 2022 were enrolled in this prospective study, among whom 120 had IVIG-sensitive KD and 24 had IVIG-resistant KD. NLRP3, ASC, CASP1, and GSDMD were quantified in peripheral blood cells of all children by using Real-time Quantitative Polymerase Chain Reaction (QRT-PCR) assay. The enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of cytokines like IL-1β and IL-18. Logistic regression analysis was performed to identify independent risk factors for resistance to IVIG in children with KD. These meaningful variables were assigned values based on odds ratios and became components of the new risk assessment model. The prediction efficiency of this model was tested and evaluated based on the receiver operating characteristic (ROC) curves. Results: 1. IVIG-resistant KD group had significantly lower mRNA expression of CASP1 than IVIG-sensitive KD group (P< 0.05). 2. IVIG-resistant KD group had significantly higher level of serum procalcitonin (PCT) and tumor necrosis factor-α (TNF-α) and lower level of serum natrium (Na) than the IVIG-sensitive KD group (P< 0.05). 3. The assessment model had a sensitivity of 91.7% and a specificity of 69.2% in the prediction of IVIG-resistant KD (P< 0.001). Conclusion: Combined examination by CASP1 and above laboratory indexes has clinical practical value for the diagnosis of IVIG-resistant KD.
- Open Access
- 27 May 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1405012
An early predictive model for Kawasaki disease shock syndrome in children in central China
Introduction: This study aims to analyze the clinical features of Kawasaki disease (KD) shock syndrome (KDSS) and explore its early predictors.Methods: A retrospective case–control study was used to analyze KD cases from February 2016 to October 2023 in our hospital. A total of 28 children with KDSS and 307 children who did not develop KDSS were included according to matching factors. Baseline information, clinical manifestations, and laboratory indicators were compared between the two groups. Indicators of differences were analyzed based on univariate analysis; binary logistic regression analysis was used to identify the risk factors for KDSS, and then receiver operating characteristic analysis was performed to establish a predictive score model for KDSS.Results: Elevated neutrophil-to-lymphocyte ratio(NLR) and decreased fibrinogen (FIB) and Na were independent risk factors for KDSS; the scoring of the above risk factors according to the odds ratio value eventually led to the establishment of a new scoring system: NLR ≥ 7.99 (6 points), FIB ≤ 5.415 g/L (1 point), Na ≤ 133.05 mmol/L (3 points), and a total score of ≥3.5 points were high-risk factors for progression to KDSS; otherwise, they were considered to be low-risk factors.Conclusion: Children with KD with NLR ≥ 7.99, FIB ≤ 5.415 g/L, and Na ≤ 133.05 mmol/L, and those with two or more of the above risk factors, are more likely to progress to KDSS, which helps in early clinical diagnosis and treatment.
- 27 May 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1405012
Open AccessAn early predictive model for Kawasaki disease shock syndrome in children in central China
Introduction: This study aims to analyze the clinical features of Kawasaki disease (KD) shock syndrome (KDSS) and explore its early predictors.Methods: A retrospective case–control study was used to analyze KD cases from February 2016 to October 2023 in our hospital. A total of 28 children with KDSS and 307 children who did not develop KDSS were included according to matching factors. Baseline information, clinical manifestations, and laboratory indicators were compared between the two groups. Indicators of differences were analyzed based on univariate analysis; binary logistic regression analysis was used to identify the risk factors for KDSS, and then receiver operating characteristic analysis was performed to establish a predictive score model for KDSS.Results: Elevated neutrophil-to-lymphocyte ratio(NLR) and decreased fibrinogen (FIB) and Na were independent risk factors for KDSS; the scoring of the above risk factors according to the odds ratio value eventually led to the establishment of a new scoring system: NLR ≥ 7.99 (6 points), FIB ≤ 5.415 g/L (1 point), Na ≤ 133.05 mmol/L (3 points), and a total score of ≥3.5 points were high-risk factors for progression to KDSS; otherwise, they were considered to be low-risk factors.Conclusion: Children with KD with NLR ≥ 7.99, FIB ≤ 5.415 g/L, and Na ≤ 133.05 mmol/L, and those with two or more of the above risk factors, are more likely to progress to KDSS, which helps in early clinical diagnosis and treatment.
- Open Access
- 27 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Combination of S100A12/TLR2 signaling molecules and clinical indicators in a new predictive model for IVIG-resistant Kawasaki disease
Although intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) presents with persistent inflammatory stimulation of the blood vessels and an increased risk of coronary artery dilatation. However, the pathogenesis of this disease is unclear, with no established biomarkers to predict its occurrence. This study intends to explore the utility of S100A12/TLR2-related signaling molecules and clinical indicators in the predictive modeling of IVIG-resistant KD. The subjects were classified according to IVIG treatment response: 206 patients in an IVIG-sensitive KD group and 49 in an IVIG-resistant KD group. Real-time PCR was used to measure the expression of S100A12, TLR2, MYD88, and NF-κB in peripheral blood mononuclear cells of patients, while collecting demographic characteristics, clinical manifestations, and laboratory test results of KD children. Multi-factor binary logistic regression analysis identified procalcitonin (PCT) level (≥ 0.845 ng/mL), Na level (≤ 136.55 mmol/L), and the relative expression level of S100A12 (≥ 10.224) as independent risk factors for IVIG-resistant KD and developed a new scoring model with good predictive ability to predict the occurrence of IVIG-resistant KD.
- 27 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessCombination of S100A12/TLR2 signaling molecules and clinical indicators in a new predictive model for IVIG-resistant Kawasaki disease
Although intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) presents with persistent inflammatory stimulation of the blood vessels and an increased risk of coronary artery dilatation. However, the pathogenesis of this disease is unclear, with no established biomarkers to predict its occurrence. This study intends to explore the utility of S100A12/TLR2-related signaling molecules and clinical indicators in the predictive modeling of IVIG-resistant KD. The subjects were classified according to IVIG treatment response: 206 patients in an IVIG-sensitive KD group and 49 in an IVIG-resistant KD group. Real-time PCR was used to measure the expression of S100A12, TLR2, MYD88, and NF-κB in peripheral blood mononuclear cells of patients, while collecting demographic characteristics, clinical manifestations, and laboratory test results of KD children. Multi-factor binary logistic regression analysis identified procalcitonin (PCT) level (≥ 0.845 ng/mL), Na level (≤ 136.55 mmol/L), and the relative expression level of S100A12 (≥ 10.224) as independent risk factors for IVIG-resistant KD and developed a new scoring model with good predictive ability to predict the occurrence of IVIG-resistant KD.
- Open Access
- 19 December 2023
- Published by Springer Nature in BMC Pediatrics
- Vol. 23 (1) , 1-11
The expression of autophagy markers in IVIG-resistant Kawasaki disease and the establishment of prediction model
Background: The aim of this study was to find early predictors of Intravenous Immunoglobulin (IVIG)-Resistant Kawasaki Disease. Methods: Patients diagnosed with Kawasaki disease were enrolled in this study. Univariate analysis and multiple logistic regression were used to analyze the clinical characteristics and laboratory findings of patients in both groups before IVIG treatment. Independent predictors of Intravenous Immunoglobulin-Resistant Kawasaki Disease were analyzed, and a prediction model for children with Intravenous Immunoglobulin-Resistant Kawasaki Disease was constructed. Results: A total of 108 children (67 males and 41 females) with IVIG-sensitive Kawasaki disease and 31 children (20 males and 11 females) with IVIG-resistant Kawasaki disease participated in this study. Compared with the IVIG-sensitive group, the duration of hospitalization, ALT, AST, GLB, r-GT, IgG, PCT, and ESR was elevated in the IVIG-resistant KD group, and ATG16L1, LC3II, BECN1, RBC, HGB, ALB, A/G, and CK were significantly lower (P < 0.05). mRNA expression of ESR, BECN1, and LC3II were independent risk factors for IVIG-resistant Kawasaki disease. A logistic regression model and scoring system were established, and the cut-off values of independent risk factors were derived from ROC curves: ESR ≥ 79.5 mm/h, BECN1 ≤ 0.645, LC3II ≤ 0.481. A new scoring system was established according to the respective regression coefficients as follows: ESR ≥ 79.5 mm/h (1 point), BECN1 ≤ 0.645 (1 point). LC3II ≤ 0.481 (2 points), 0–1 as low risk for IVIG non-response, and ≥ 2 as high risk. Applied to this group of study subjects, the sensitivity was 87.10%, specificity 83.33%, Youden index 0.70, AUC 0.9. Conclusions: Autophagy markers ATG16L1, BECN1, and LC3II are down-regulated in the expression of IVIG -resistant KD. ESR, BECN1, and LC3II mRNAs are independent risk factors for IVIG-resistant KD and may be involved in the development of IVIG-resistant KD. This study established a new model that can be used to predict IVIG-resistant KD, and future validation in a larger population is needed.
- 19 December 2023
- Published by Springer Nature in BMC Pediatrics
- Vol. 23 (1) , 1-11
Open AccessThe expression of autophagy markers in IVIG-resistant Kawasaki disease and the establishment of prediction model
Background: The aim of this study was to find early predictors of Intravenous Immunoglobulin (IVIG)-Resistant Kawasaki Disease. Methods: Patients diagnosed with Kawasaki disease were enrolled in this study. Univariate analysis and multiple logistic regression were used to analyze the clinical characteristics and laboratory findings of patients in both groups before IVIG treatment. Independent predictors of Intravenous Immunoglobulin-Resistant Kawasaki Disease were analyzed, and a prediction model for children with Intravenous Immunoglobulin-Resistant Kawasaki Disease was constructed. Results: A total of 108 children (67 males and 41 females) with IVIG-sensitive Kawasaki disease and 31 children (20 males and 11 females) with IVIG-resistant Kawasaki disease participated in this study. Compared with the IVIG-sensitive group, the duration of hospitalization, ALT, AST, GLB, r-GT, IgG, PCT, and ESR was elevated in the IVIG-resistant KD group, and ATG16L1, LC3II, BECN1, RBC, HGB, ALB, A/G, and CK were significantly lower (P < 0.05). mRNA expression of ESR, BECN1, and LC3II were independent risk factors for IVIG-resistant Kawasaki disease. A logistic regression model and scoring system were established, and the cut-off values of independent risk factors were derived from ROC curves: ESR ≥ 79.5 mm/h, BECN1 ≤ 0.645, LC3II ≤ 0.481. A new scoring system was established according to the respective regression coefficients as follows: ESR ≥ 79.5 mm/h (1 point), BECN1 ≤ 0.645 (1 point). LC3II ≤ 0.481 (2 points), 0–1 as low risk for IVIG non-response, and ≥ 2 as high risk. Applied to this group of study subjects, the sensitivity was 87.10%, specificity 83.33%, Youden index 0.70, AUC 0.9. Conclusions: Autophagy markers ATG16L1, BECN1, and LC3II are down-regulated in the expression of IVIG -resistant KD. ESR, BECN1, and LC3II mRNAs are independent risk factors for IVIG-resistant KD and may be involved in the development of IVIG-resistant KD. This study established a new model that can be used to predict IVIG-resistant KD, and future validation in a larger population is needed.